BCG PPD-specific IFN-γ ELISpot Responses Weeks after immunization

Slides:

Advertisements

Similar presentations

Assays of Immune Function. Some Definitions BrdU: bromodeoxyuridine (incorporated into DNA during cell division) CBA: cytometric bead array DC: dendritic.

Advertisements

Detection of Immune Responses in Mucosal T-cells in Kenya Jackton Indangasi 2, Hannah Cheeseman 1, Onyango J. I. Obila 2, Simon Ogola 2, Robert Langat.

Flow cytometry to evaluate vaccine-induced T cell responses: standardized analysis of large numbers of FCS files Stephen De Rosa, M.D. HVTN Laboratory.

V43 DNA-Ad26-ALVAC Study ELISpot SFC/Million PBMC.

CD4 T cells: fates, functions, and faults by Jinfang Zhu, and William E. Paul Blood Volume 112(5): September 1, 2008 ©2008 by American Society.

Fig. 1. Antibody response in mice immunized with VLP. Three groups of mice (n=10/group) were used in this study. Mice in groups 1 and 2 were immunized.

The AIDS resistance of naturally SIV-infected sooty mangabeys is independent of cellular immunity to the virus by Richard Dunham, Paola Pagliardini, Shari.

Fig. 3. IL-4, IFN-γ, and IL-17 production from α-GalCer-stimulated iNKT cells following FlaB treatment of PBMC cultures from asthma patients and healthy.

Volume 17, Issue 9, Pages (September 2015)

Supplementary Figure 3 Antigen-specific responses are enhanced by stimulation in an in vitro stimulation (IVS) assay, as well as with stimulation using.

Fig. 2. Comparison of the Th1/Th2 ratio and the percentages of Th1 and Th2 cells between normal and allergic individuals. (A) The Th1/Th2 ratio observed.

Fig. 1. Percentage of patients with AS, with RA and of normal controls responding to the in vitro stimulation with the G1 domain of the proteoglycan aggrecan.

Figure 6. The effect of GV1001 on ENO1-induced pro-inflammatory cytokine production in RA PBMCs. RA PBMCs were pre-treated with GV1001 (100 µM) for 1 h.

Fig. 3. Activation and Th1 differentiation of the P25 TCR-Tg CD4+ T cells after BCG lung infection. The N-P25 TCR-Tg mice were i.t.

Figure 1. Study participant flowchart

Anifrolumab inhibits cytokine production, plasmacytoid dendritic cell (pDC) activation and the type I (interferon gene signature) IFN gene signature. Anifrolumab.

Engineering Human Peripheral Blood Stem Cell Grafts that Are Depleted of Naïve T Cells and Retain Functional Pathogen-Specific Memory T Cells Marie Bleakley,

Volume 19, Issue 12, Pages (December 2011)

Volume 143, Issue 5, Pages (November 2012)

Functionally Active HIV-Specific T Cells that Target Gag and Nef Can Be Expanded from Virus-Naïve Donors and Target a Range of Viral Epitopes: Implications.

Volume 137, Issue 4, Pages (October 2009)

Volume 25, Issue 2, Pages (February 2017)

IFNα, but not IFNλ, treatment induces cytokine secretion from human immune cells IFNα, but not IFNλ, treatment induces cytokine secretion from human immune.

Proteins Peptides DnaK Peptides + DnaK

Volume 25, Issue 11, Pages (November 2017)

Volume 22, Issue 2, Pages (February 2014)

Volume 22, Issue 5, Pages (May 2014)

Volume 65, Issue 4, Pages (April 2004)

Human CD8+ memory and EBV-specific T cells show low alloreactivity in vitro and in CD34+ stem cell–engrafted NOD/SCID/IL-2Rγcnull mice Simone Thomas,

Volume 25, Issue 5, Pages (May 2017)

Covering the Cover Gastroenterology

Figure 5 Cytokine release and stimulation of cells during alemtuzumab treatment Cytokine release and stimulation of cells during alemtuzumab treatment.

Volume 19, Issue 11, Pages (November 2011)

Targeting Fel d 1 to FcγRI induces a novel variation of the TH2 response in subjects with cat allergy Kathryn E. Hulse, BS, Amanda J. Reefer, MS, Victor.

Peptide ID# Pulsed to T2-A24 Cells

Volume 143, Issue 1, Pages e3 (July 2012)

Volume 34, Issue 5, Pages (May 2011)

Positive Atopy Patch Test Reaction to Malassezia furfur in Atopic Dermatitis Correlates with a T Helper 2-like Peripheral Blood Mononuclear Cells Response

Tetramer staining performed to determine frequencies of epitope-specific T cells after clearance of HPV16 infection but prior to isolation of T-cell clones.

Volume 23, Issue 5, Pages (May 2018)

Volume 19, Issue 2, Pages (February 2011)

Volume 44, Issue 1, Pages (January 2016)

Volume 147, Issue 4, Pages e8 (October 2014)

Volume 18, Issue 9, Pages (September 2010)

Non-typeable Haemophilus influenzae (NTHi)-stimulated cytokine production. Non-typeable Haemophilus influenzae (NTHi)-stimulated cytokine production. Peripheral.

Etifoxine modulation of T‐cell activity during EAE

Direct ex vivo analysis of allergen-specific CD4+ T cells

Epicutaneous Application of CpG Oligodeoxynucleotides with Peptide or Protein Antigen Promotes the Generation of CTL Sandra K. Klimuk, Hossain M. Najar,

MP cells can mediate resistance in infectious models that induce TH1-type immunity. MP cells can mediate resistance in infectious models that induce TH1-type.

Introduction. Activation of HIV-Specific CD8+ T Cells from HIV+ Donors by Vesatolimod.

Figure 4 Increased susceptibility of MIF−/− CD4+ T cells to immunosuppression by Dex in EAE (A) MOG35-55 peptide-activated donor cells from wild-type (Wt)

Figure 2 Natalizumab increases expression of proinflammatory genes and cytokines by CD49d+ memory CD4 cells Natalizumab increases expression of proinflammatory.

Figure 3 DMF promotes an anti-inflammatory cytokine B-cell profile

Figure 2 Effect of DMF therapy on the T helper cell repertoire and cytokine production Effect of DMF therapy on the T helper cell repertoire and cytokine.

Induction of IL-3–secreting CD4+ T cells.

Members of IL-1 family of cytokines favor the generation of IL-3–secreting CD4+ T cells in vitro. Members of IL-1 family of cytokines favor the generation.

CD8 T cell memory alters the immune profile in enhanced HLH without altering viral load. CD8 T cell memory alters the immune profile in enhanced HLH without.

Figure 2 Effect of Dex on cytokine production by MIF−/− or Wt T cells in EAE Wild-type (Wt) and macrophage migration inhibitory factor (MIF)−/− mice were.

Volume 25, Issue 5, Pages (May 2017)

Figure 3. Enhancement of cytokine production by CD8+ T cells at TT

Volume 26, Issue 6, Pages (June 2018)

Figure 1. T-cell immunogenicity of HZ DNA vaccines in C57BL/6 mice

PD-1 inhibition stimulates the proliferation and cytokine secretion of exhausted/senescent CD8+ T cells in vitro. PD-1 inhibition stimulates the proliferation.

Increased levels of inflammation in mo-DCs translate into higher numbers of specific CD8 T-cell responses. Increased levels of inflammation in mo-DCs translate.

HLA-A*0201 restriction of SSX2-derived p stimulated CD8+ T-cells.

Sang Kyun Ahn, Vanessa Tran, Andrea Leung, Mark Ng, Ming Li, Jun Liu

Molecular Therapy - Methods & Clinical Development

Serum IFNγ and immune responses following tecemotide/cisplatin combination treatment in a urethane-induced hMUC1.Tg lung cancer mouse model. Serum IFNγ.

Antigen-specific cytokine-producing cells (IFN-γ and IL-5) detected by ELISPOT assay 3 weeks after the 3rd immunization. Antigen-specific cytokine-producing.

Volume 25, Issue 2, Pages (February 2017)

Presentation transcript:

BCG PPD-specific IFN-γ ELISpot Responses Weeks after immunization Figure #1 BCG PPD-specific IFN-γ ELISpot Responses rBCG rBCG rAd5 SFC/106 PBMC Weeks after immunization Median

SIV-specific IFN-γ ELISpot Responses Figure #2 SIV-specific IFN-γ ELISpot Responses a. Gag peptide pool stimulated b. p11C peptide stimulated rBCG rBCG rAd5 SFC/106 PBMC c. Pol peptide pool stimulated d. Env peptide pool stimulated Weeks after immunization Median

% Tetramer binding CD8+ T cells Figure #3 SIV-specific CD8+ T-cell Responses after In Vitro Culture Stimulation of PBMC with p11C Peptide and Interleukin-2 % Tetramer binding CD8+ T cells Monkey rBCG dose (cfu) Route

SIV Gag-specific IFN-γ ELISpot Responses by Dosage Figure #4a SIV Gag-specific IFN-γ ELISpot Responses by Dosage 2 weeks after rAd5 4 weeks after rAd5 SFC/106 PBMC 10 weeks after rAd5 21 weeks after rAd5

SIV Pol-specific IFNγ ELISpot Responses by Dosage Figure #4b SIV Pol-specific IFNγ ELISpot Responses by Dosage 2 weeks after rAd5 4 weeks after rAd5 SFC/106 PBMC 10 weeks after rAd5 21 weeks after rAd5

SIV Gag-specific IFNγ ELISpot Responses by Route Figure #5a SIV Gag-specific IFNγ ELISpot Responses by Route 2 weeks after rAd5 4 weeks after rAd5 SFC/106 PBMC * Mann-Whitney Test Kruskall-Wallis Test: p=0.0079; Dunn's Multiple Comparison (adjusted for multiple comparison): p<0.05 for BCG IV vs. Control: significant p<0.05 for BCG ID vs. Control: significant p>0.05 for all other group comparisons * Mann-Whitney Test Kruskall-Wallis Test: p=0.0780; Dunn's Multiple Comparison (adjusted for multiple comparison): p>0.05 between all groups

SIV Gag-specific IFN-γ ELISpot Responses by Route Figure #5b SIV Gag-specific IFN-γ ELISpot Responses by Route 10 weeks after rAd5 21 weeks after rAd5 SFC/106 PBMC * Mann-Whitney Test Kruskall-Wallis Test: p=0.0406; Dunn's Multiple Comparison (adjusted for multiple comparison): p>0.05 between all groups * Mann-Whitney Test Kruskall-Wallis Test: p=0.0227; Dunn's Multiple Comparison (adjusted for multiple comparison): p<0.05 for ID vs. Control, p>0.05 for all other group comparisons

SIV Pol-specific IFN-γ ELISpot Responses by Route Figure #5c SIV Pol-specific IFN-γ ELISpot Responses by Route 2 weeks after rAd5 4 weeks after rAd5 SFC/106 PBMC * Mann-Whitney Test Kruskall-Wallis Test: p=0.0146; Dunn's Multiple Comparison (adjusted for multiple comparison): p<0.05 for BCG IV vs. Control: significant p>0.05 for all other group comparisons * Mann-Whitney Test Kruskall-Wallis-Test: p= 0.2101; Dunn's Multiple Comparison (adjusted for multiple comparison): p>0.05 between all groups

SIV Pol-specific IFNγ ELISpot Responses by Route Figure #5d SIV Pol-specific IFNγ ELISpot Responses by Route 10 weeks after rAd5 21 weeks after rAd5 SFC/106 PBMC * Mann-Whitney Test Kruskall-Wallis Test: p=0.3853; Dunn's Multiple Comparison (adjusted for multiple comparison): p>0.05 between all groups * Mann-Whitney Test Kruskall-Wallis Test: p=0.2565; Dunn's Multiple Comparison (adjusted for multiple comparison): p>0.05 between all groups

SIV Gag-specific Tetramer Responses by Dosage Figure #6 SIV Gag-specific Tetramer Responses by Dosage 2 weeks after rAd5 4 weeks after rAd5 % Tetramer binding CD8+ T cells 10 weeks after rAd5 21 weeks after rAd5

SIV Gag-specific p11C Tetramer Responses by Route Figure #7a SIV Gag-specific p11C Tetramer Responses by Route 2 weeks after rAd5 4 weeks after rAd5 % Tetramer binding CD8+ T cells * Mann-Whitney Test Kruskall-Wallis Test: p=0.0132; Dunn's Multiple Comparison (adjusted for multiple comparison): p<0.05 for IV vs. Control: significant p<0.05 for ID vs. Control: significant p>0.05 for all other group comparisons * Mann-Whitney Test Kruskall-Wallis Test: p=0.1733; Dunn's Multiple Comparison (adjusted for multiple comparison): p>0.05 for all groups Median ± Interquartile Range

SIV Gag-specific p11C Tetramer Responses by Route Figure #7b SIV Gag-specific p11C Tetramer Responses by Route 10 weeks after rAd5 21 weeks after rAd5 % Tetramer binding CD8+ T cells * Mann-Whitney Test Kruskall-Wallis Test : p=0.0869; Dunn's Multiple Comparison (adjusted for multiple comparison): p>0.05 for all groups * Mann-Whitney Test Kruskall-Wallis Test : p=0.0823; Dunn's Multiple Comparison (adjusted for multiple comparison): p>0.05 for all groups Median ± Interquartile Range

SIV Gag-specific p11C Tetramer Responses by Route and Dosage rBCG rBCG rAd5 Figure #8 % Tetramer binding CD8+ T cells SIV Gag-specific p11C Tetramer Responses by Route and Dosage Median Weeks after immunization

SIV Pol-specific p68 Tetramer Responses Figure #9 SIV Pol-specific p68 Tetramer Responses rAd5 % Tetramer binding CD8+ T cells Weeks after immunization Median

ICS SIV Gag Peptide Pool Stimulation Figure #10 ICS SIV Gag Peptide Pool Stimulation 3 weeks after rAd5 % Cytokine+ Gated on CD8+3+ % Cytokine+ Gated on CD4+3+ Median ± Interquartile Range

ICS p11C Peptide Stimulation Figure #11a ICS p11C Peptide Stimulation A) rBCG IV rBCG ID rAd5 % cytokine+ B) CD8+ T cells IFN- + - + + - - + IL-2 + + - + - + - TNF-α + + + - + - - Median ± Interquartile Range

ICS p11C Peptide Stimulation Figure #11b ICS p11C Peptide Stimulation p11C CD28+ Total cytokine IFN-γ TNF-α IL-2 Median ± Interquartile Range